Top

The International Journal of Cardiovascular Imaging

Published in:

01-04-2010 | Original Paper

Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification

Authors: Lyndia C. Brumback, Richard Kronmal, Susan R. Heckbert, Hanyu Ni, W. Gregory Hundley, João A. Lima, David A. Bluemke

Published in: The International Journal of Cardiovascular Imaging | Issue 4/2010

Abstract

Methods to index left ventricular (LV) mass, measured by cardiovascular magnetic resonance (CMR), for body size have not been investigated. The purposes of this study were to develop allometric indices for LV mass measured by CMR and compare estimates of the prevalence and predictive value of LV hypertrophy defined by a new allometric height-weight index, LV mass/body surface area (BSA), height indices (a new allometric height index; and previously derived indices from echocardiographic measurements: LV mass/height², LV mass/height^2.7), and non-indexed LV mass. 5,004 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with CMR measurements of LV mass and no clinical cardiovascular disease at baseline were followed for a median of 4.1 years. The new indices and limits for hypertrophy (95th percentile) were derived from 822 normal-weight, normotensive, non-diabetic MESA participants. 107 events (coronary heart disease or stroke) were observed. The estimated prevalence of hypertrophy at baseline and hazard ratio for event associated with hypertrophy were 8% and 2.4 with the new allometric height-weight index, 11% and 2.2 with LV mass/BSA, 23–24% and 2.0–2.1 with height indices, and 20% and 1.7 with non-indexed LV mass. A statistically significant difference was detected between the hazard ratios based on the new height-weight index and non-indexed LV mass. The prevalence of hypertrophy is higher for indices that do not account for weight. The predictive value of hypertrophy is significantly better with the new allometric height-weight index than with non-indexed LV mass and may be better than indices without weight.

Kannel WB, Gordon T, Castelli WP, Margolis JR (1970) Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 72:813–822PubMed

Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1989) Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The framingham heart study. Ann Intern Med 110:101–107PubMed

Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561–1566PubMed

Tsang TS, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR, Seward JB (2003) Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol 42:1199–1205CrossRefPubMed

Gottdiener JS, Arnold AM, Aurigemma GP, Polak FJ, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC (2000) Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35:1628–1637CrossRefPubMed

Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS (1992) The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 117:831–836PubMed

Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB (2006) Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27:65–75CrossRefPubMed

Aronow WS, Ahn C, Kronzon I, Koenigsberg M (1991) Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol 67:295–299CrossRefPubMed

Kupari M, Lindroos M, Iivanainen AM, Heikkila J, Tilvis R (1997) Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med 241:387–394CrossRefPubMed

10.

Natori S, Lai S, Finn P, Gomes AS, Hundley WG, Jerosch-Herold M, Pearson G, Sinha S, Arai A, Lima JA, Bluemke DA (2006) Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity. Am J Roentgenol 186:S357–S365CrossRef

11.

Dewey FE, Rosenthal D, Murphy DJ Jr, Froelicher VF, Ashley EA (2008) Does size matter? Clinical applications of scaling cardiac size and function for body size. Circulation 117:2279–2287CrossRefPubMed

12.

Dubois D, Dubois EF (1916) A formula to estimate the approximate surface if height and weight are known. Arch Intern Med 17:863–871

13.

de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH (1992) Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 20:1251–1260PubMedCrossRef

14.

de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH (1994) Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 23:600–606PubMed

15.

de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH (1995) Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 25:1056–1062CrossRefPubMed

16.

Lauer MS, Anderson KM, Larson MG, Daniel L (1994) A new method for indexing left ventricular mass for differences in body size. Am J Cardiol 74:487–491CrossRefPubMed

17.

Daniels SR, Kimball TR, Morrison JA, Khoury P, Meyer RA (1995) Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. Am J Cardiol 76:699–701CrossRefPubMed

18.

Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O’Leary D, Saad MF, Shea S, Szklo M, Tracy RP (2002) Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156:871–881CrossRefPubMed

19.

NHLBI Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 6: 51S–209S

20.

WHO Consultation on Obesity. Obesity: Preventing and Managing the Global Epidemic. Geneva, Switzerland: World Health Organization; 2000. WHO Technical Report Series 894

21.

1997 Joint National Committee (1997) The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 157: 2413–2446

22.

Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P (2003) Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167CrossRefPubMed

23.

Chang JJ, Rabinowitz D, Shea S (2003) Sources of variability in blood pressure measurement using the Dinamap PRO 100 automated oscillometric device. Am J Epidemiol 158:1218–1226CrossRefPubMed

24.

Hume R (1966) Prediction of lean body mass from height and weight. J Clin Path 19:389–391CrossRefPubMed

25.

Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O’Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA (2008) Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358:1336–1345CrossRefPubMed

26.

Vasan RS, Larson MG, Levy D, Evans JC, Benjamin EJ (1997) Distribution and categorization of echocardiographic measurements in relation to reference limits. The Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation. Circulation 96:1863–1873PubMed

27.

Salton CJ, Chuang ML, O’Donnell CJ, Kupka MJ, Larson MG, Kissinger KV, Edelman RR, Levy D, Manning WJ (2002) Gender differences and normal left ventricular anatomy in an adult population free of hypertension. J Am Coll Cardiol 39:1055–1060CrossRefPubMed

28.

Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK (1997) Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 29:641–647CrossRefPubMed

29.

Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK (1996) The progression from hypertension to congestive heart failure. JAMA 275:1557–1562CrossRefPubMed

30.

Grossman W, Jones D, McLaurin LP (1975) Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56:56–64CrossRefPubMed

31.

Katz AM (1990) Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 322:100–110PubMed

32.

Lauer MS, Anderson KM, Levy D (1991) Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: the framingham heart study. J Am Coll Cardiol 18:1287–1294PubMedCrossRef

33.

Jilaihawi H, Greaves S, Rouleau JL, Pfeffer MA, Solomon SD (2003) Healing and early afterload reducing therapy trial investigators. Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction. Am J Cardiol 91:723–726CrossRefPubMed

34.

Lauer MS, Anderson KM, Kannel WB, Levy D (1991) The impact of obesity on left ventricular mass and geometry. The framingham heart study. JAMA 266:231–236CrossRefPubMed

35.

Lee M, Gardin JM, Lynch JC, Smith VE, Tracy RP, Savage PJ, Szklo M, Ward BJ (1997) Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the cardiovascular health study. Am Heart J 133:36–43CrossRefPubMed

36.

Gardin JM, Arnold A, Gottdiener JS, Wong ND, Fried LP, Klopfenstein HS, O’Leary DH, Tracy R, Kronmal R (1997) Left ventricular mass in the elderly. The cardiovascular health study. Hypertension 29:1095–1103PubMed

37.

Heckbert SR, Post W, Pearson GD, Arnett DK, Gomes AS, Jerosch-Herold M, Hundley WG, Lima JA, Bluemke DA (2006) Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. J Am Coll Cardiol 48:2285–2292CrossRefPubMed

38.

Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K (2004) Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110:1456–1462CrossRefPubMed

39.

Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B (2004) Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292:2350–2356CrossRefPubMed

40.

Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H (2002) LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288:1491–1498CrossRefPubMed

41.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B (2004) LIFE study investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292:2343–2349CrossRefPubMed

42.

Gardin JM, Lauer MS (2004) Left ventricular hypertrophy: the next treatable, silent killer? JAMA 292:2396–2398CrossRefPubMed

43.

de Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, Lee ET, Devereux RB (2005) Normalization for body size and population-attributable risk of left ventricular hypertrophy. The strong heart study. Am J Hypertens 18:191–196CrossRefPubMed

44.

de Simone G, Devereux RB, Maggioni AP, Gorini M, de Divitiis O, Verdecchia P (2005) Different normalizations for body size and population attributable risk of left ventricular hypertrophy: the MAVI study. Am J Hypertens 18:1288–1293CrossRefPubMed

45.

Marcus JT, DeWaal LK, Gotte MJ, van der Geest RJ, Heethaar RM, Van Rossum AC (1999) MRI-derived left ventricular function parameters and mass in healthy young adults: relation with gender and body size. Int J Card Imag 15:411–419CrossRef

46.

Sandstede J, Lipke C, Beer M, Hofmann S, Pabst T, Kenn W, Neubauer S, Hahn D (2000) Age- and gender-specific differences in left and right ventricular cardiac function and mass determined by cine magnetic resonance imaging. Eur Radiol 10:438–442CrossRefPubMed

47.

Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU (2003) Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging 17:323–329CrossRefPubMed

48.

Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr (1999) Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1:7–21CrossRefPubMed

Title: Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification
Authors: Lyndia C. Brumback
Richard Kronmal
Susan R. Heckbert
Hanyu Ni
W. Gregory Hundley
João A. Lima
David A. Bluemke
Publication date: 01-04-2010
Publisher: Springer Netherlands
Published in: The International Journal of Cardiovascular Imaging / Issue 4/2010
Print ISSN: 1569-5794
Electronic ISSN: 1875-8312
DOI: https://doi.org/10.1007/s10554-010-9584-5

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Assessment of coronary artery calcium by using volumetric 320-row multi-detector computed tomography: comparison of 0.5 mm with 3.0 mm slice reconstructions

Recent developments and new perspectives on imaging of atherosclerotic plaque: role of anatomical, cellular and molecular MRI part III

How reliable are 40 MHz IVUS and 64-slice MDCT in characterizing coronary plaque composition? An ex vivo study with histopathological comparison

Left ventricular mass assessment by CMR; how to define the optimal index

Thrombosis of a bileaflet prosthetic mitral valve: a real-time three-dimensional transesophageal echocardiography perspective

Prediction of subclinical left ventricular dysfunction with longitudinal two-dimensional strain and strain rate imaging in patients with mitral stenosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page